Does TAFAMIDIS MEGLUMINE Cause Disease progression? 157 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 157 reports of Disease progression have been filed in association with TAFAMIDIS MEGLUMINE (Vyndaqel). This represents 3.6% of all adverse event reports for TAFAMIDIS MEGLUMINE.
157
Reports of Disease progression with TAFAMIDIS MEGLUMINE
3.6%
of all TAFAMIDIS MEGLUMINE reports
68
Deaths
35
Hospitalizations
How Dangerous Is Disease progression From TAFAMIDIS MEGLUMINE?
Of the 157 reports, 68 (43.3%) resulted in death, 35 (22.3%) required hospitalization, and 3 (1.9%) were considered life-threatening.
Is Disease progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAFAMIDIS MEGLUMINE. However, 157 reports have been filed with the FAERS database.
What Other Side Effects Does TAFAMIDIS MEGLUMINE Cause?
Death (1,196)
Cardiac failure (519)
Off label use (418)
Dyspnoea (227)
Product use in unapproved indication (202)
Cardiac failure chronic (188)
Atrial fibrillation (164)
Fatigue (163)
Condition aggravated (144)
Asthenia (125)
What Other Drugs Cause Disease progression?
RITUXIMAB (7,282)
CYCLOPHOSPHAMIDE (7,100)
DOXORUBICIN (6,165)
VINCRISTINE (5,252)
PREDNISONE (5,096)
BEVACIZUMAB (4,653)
DEXAMETHASONE (4,545)
CARBOPLATIN (4,538)
CAPECITABINE (3,808)
ETOPOSIDE (3,776)
Which TAFAMIDIS MEGLUMINE Alternatives Have Lower Disease progression Risk?
TAFAMIDIS MEGLUMINE vs TAFASITAMAB
TAFAMIDIS MEGLUMINE vs TAFASITAMAB-CXIX
TAFAMIDIS MEGLUMINE vs TAFINLAR
TAFAMIDIS MEGLUMINE vs TAFLUPROST
TAFAMIDIS MEGLUMINE vs TAGRAXOFUSP-ERZS